IMC Chicago’s CorMedix CRMD Stock Holding History

IMC Chicago’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$587K	Buy	74,800 +18,300	+32%	+$145K	﹤0.01%	4457
2026 Q1	$384K	Buy	56,500 +8,600	+18%	+$63.6K	﹤0.01%	4322
2025 Q4	$557K	Buy	+47,900	New	+$530K	﹤0.01%	3406

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

OAM

Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

IMC Chicago's CRMD Position: Q1 2026 in Review

IMC Chicago sold out of CorMedix (CRMD) in Q1 2026, closing a stake of 27,342 shares — an estimated $202K sold.

IMC Chicago first reported a position in CRMD in Q4 2025 and held it in 1 quarter. The position peaked at $318K in Q4 2025. 188 funds tracked by Wall St. Rank hold CRMD as of Q1 2026.

IMC Chicago reported no remaining CorMedix position as of Q1 2026 after selling out during the quarter.
IMC Chicago sold 27,342 CorMedix shares in Q1 2026, an estimated $202K.
IMC Chicago first reported a position in CorMedix in Q4 2025 and held it in 1 quarter.
IMC Chicago's CorMedix position peaked at $318K in Q4 2025.
188 funds tracked by Wall St. Rank held CorMedix as of Q1 2026.

Based on IMC Chicago's 13F filing for Q1 2026, filed 5 May 2026.